# QuidelOrtho Corporation – Consensus ‘buy’ rating and 72.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/quidelortho-corporation-consensus-buy-rating-and-72.0-upside-potential/4121130309
- Published: 2023-10-20T13:20:26+01:00
- Author: Charlotte Edwards

**QuidelOrtho Corporation** which can be found using ticker (QDEL) now have 7 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between 168 and 81 calculating the average target price
we see $118.14. Now with the previous closing price of $68.69 this indicates there
is a potential upside of 72.0%. Also worth taking note is the 50 day moving average
now sits at $74.45 while the 200 day moving average is $83.75. The company has a
market cap of 4.48B. The stock price for the company is currently 67.03 USD

 The potential market cap would be $7,699,952,217 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 47.43 and
a 2.41% return on assets.

QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in
the development and manufacturing of advanced technologies in diagnostic testing.
Its capabilities include immunoassay and molecular testing, clinical chemistry and
transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics,
Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology,
Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform,
VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business
includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under
various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells,
InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel,
QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage,
Virena, and Vitros.

Share on: